metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			DCR
hepatocell cancer (HCC) hepatocell cancer (HCC)
versus placebo
	durvalumab plus bevacizumab vs. placebo	1	-
	pembrolizumab based treatment vs. placebo	1	-
versus sorafenib
	Tislelizumab vs. sorafenib	1	-
versus Standard of Care (SoC)
	sintilimab vs. Standard of Care (SoC)	1	-
mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)
versus Standard of Care (SoC)
	atezolizumab plus bevacizumab vs. Standard of Care (SoC)	1	-
	sintilimab vs. Standard of Care (SoC)	1	-
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus lenvatinib
	pembrolizumab plus lenvatinib vs. lenvatinib	1	-
versus placebo
	durvalumab plus bevacizumab vs. placebo	1	-
versus sorafenib
	atezolizumab plus bevacizumab vs. sorafenib	1	-
	atezolizumab plus cabozantinib vs. sorafenib	1	-
	camrelizumab based treatment vs. sorafenib	1	-
	nivolumab alone vs. sorafenib	1	-
	sintilimab vs. sorafenib	1	-
	Tislelizumab vs. sorafenib	1	-
mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)
versus placebo
	pembrolizumab alone vs. placebo	1
	pembrolizumab based treatment vs. placebo	1